Samsung Biologics Co., Ltd. (KRX:207940) closed at ₩1,447,000 on Friday, September 4. The shares fell 2.0%. The company's market capitalisation was ₩67 trillion at Friday's close. That's roughly $48bn at an approximate ₩1,400 per dollar. The shares have now fallen about 26% from their 52-week high of ₩1,965,000. Most of that drop came since the August 28 announcement of a ₩3tn rights issue.
This week the company tried to explain the rights issue by publishing what it is for. Korean press, citing a company briefing on September 3, reported a ₩15.4tn investment roadmap running through 2034. The pieces are specific. About ₩2.7tn goes to acquire PolyPeptide Group. Plant 6 and related facilities get ₩1.9tn, and a Plant 7 expansion gets ₩1.8tn. A third bio campus takes roughly ₩7tn. US production capacity gets ₩700bn. Another ₩1.34tn goes to antibody-drug conjugate and fill-finish equipment along with small-scale contract manufacturing equipment. Management said the ₩3tn rights issue in November would be the only equity it raised. It said operating cash flow and borrowing would fund everything after. It would review dividends in three years.
My view is that the plan is smaller than it sounds. Spread over eight years, ₩15.4tn is about ₩1.9tn a year. This company generated ₩1.39tn of operating cash in the first half of 2026 alone. The plan is fundable from cash flow. That makes the rights issue a question about timing rather than about capacity. The timing is the PolyPeptide deal.
Operating cash flow was ₩767.7bn in the first quarter and ₩624.8bn in the second. That totals ₩1.39tn over six months. Annualised, that's about ₩2.8tn a year. Fiscal 2025, on the old consolidated basis that still included Samsung Bioepis, produced ₩2.25tn.
Capital spending in the first half was only ₩172.6bn. That's a pause, not a trend. The company spent ₩1.39tn on plant in fiscal 2025 and ₩1.30tn in fiscal 2024. Most went to Plant 5. The first half of 2026 is the gap between one plant finishing and the next starting.
Put the two together. The company generates ₩2.8tn a year and plans to spend ₩1.9tn a year. That leaves ₩900bn a year before any borrowing. The plan does front-load. PolyPeptide settles in November and Plant 6 construction starts soon after. But even ₩4tn to ₩5tn in the first two years is within reach of cash flow plus ordinary bank debt. Total liabilities are ₩4.29tn against ₩8.36tn of equity, which leaves room to borrow.
So why sell shares? The stated answer is that a Swiss tender offer needs certain funds on a fixed date. Equity is certain in a way that a loan syndicate closing on a deadline is not. I wrote on August 28 that the July acquisition filing said the deal would be paid from own funds and borrowings, and that the August amendment switched to rights-issue proceeds. Nothing in this week's briefing explains what changed between July and August. It explains only what the money is for.
The mix of the ₩15.4tn is informative on its own. Roughly ₩10.7tn, about 70%, is capacity in Korea. That covers Plant 6, Plant 7, and the third campus. That is the same strategy that made this company the largest biologics contract manufacturer by installed capacity. Build bioreactors at Songdo faster than anyone else, and fill them.
The other 30% is new. PolyPeptide is peptide chemistry, which Samsung Biologics doesn't have. The obesity-drug boom has made it scarce. The ₩1.34tn for antibody-drug conjugates and fill-finish is a move up the value chain from bulk antibody production. The ₩700bn in the US is a hedge against pharmaceutical onshoring rules.
For shareholders, the question is whether the 30% earns what the 70% does. The Korean plants run at a second-quarter operating margin of 44.4%. PolyPeptide lost money in each of the last three years. The company is buying a business with a different economic profile. The briefing didn't say when it expects that business to reach group margins.
The rights issue prices new shares at a 15% discount and adds about 4.9% to the count. The shares at ₩1,447,000 trade at about 37 times annualised first-half net income of ₩900bn. They also trade at about 8 times book equity of ₩8.36tn. Those are high multiples, and they were higher before the rights issue was announced.
The book multiple looks extreme because the Samsung Bioepis split in late 2025 removed ₩5.4tn of intangibles and most associated equity. That left a smaller balance sheet under the same market cap. The earnings multiple is the more useful one. And 37 times is a price for growth. The roadmap is the growth. If the third campus fills at the margins the current plants earn, the multiple is defensible. If it doesn't, the market is paying for bioreactors that will sit empty.
The first risk is the one in every capacity story. Samsung Biologics is committing to roughly ₩10.7tn of new Korean plant for a customer base that has to sign long-term contracts to fill it. The contract manufacturing market has grown fast. But Lonza, Boehringer and Fujifilm are adding capacity too. Pharmaceutical companies have begun building in-house again. Plant 6 and Plant 7 are bets that the demand curve keeps rising through 2030.
The second is dilution beyond the rights issue. Management said this is the only equity it will raise. It also said that in July, when the funding plan was own funds and borrowings. A second reversal would cost more than the first.
The third is the dividend. Reviewing dividends in three years means no dividend policy until 2029. For a company with ₩2.8tn of annual operating cash, that is a decision, not a constraint. It tells shareholders that every won of surplus for the rest of the decade goes into plants and acquisitions. Investors who wanted a return from a company this profitable will have to wait, or leave.
The company has to file the securities registration statement (증권신고서) for the rights issue with the Financial Services Commission. It must do so before the November subscription. That document must state the use of proceeds in detail and the reasons for choosing equity over debt. It is the first place the company has to put in writing what this week's briefing only said out loud.
The second checkpoint is the PolyPeptide tender result, settling November 30. If the offer succeeds, ₩2.7tn of the ₩15.4tn is spent. If it fails, the rights issue will have raised ₩3tn for a purchase that didn't happen. Then the roadmap's first line will need a replacement.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.